

C6  
CONT. threonine at position 231 and serine at position 235, or serine at position 412 and serine at position 413 of amino acid sequence of SEQ ID NO: 1.

---

C7  
6. (Amended) A reagent kit for detecting Alzheimer's disease, comprising one or more antibodies obtained by using, as an immunogen, a partial peptide comprising one or more amino acid residue(s) at the phosphorylation sites of phosphorylated tau protein in a paired helical filament and plural amino acid residues before and/or after the phosphorylation site(s) of amino acid sequence of SEQ ID NO: 1, wherein the phosphorylation site(s) are one or more amino acid residue(s) selected from the group consisting of serine at position 198, serine at position 199, threonine at position 231, serine at position 235, serine at position 262, serine at position 396, threonine at position 403, serine at position 404, serine at position 409, serine at position 412, serine at position 413, and serine at position 422 of amino acid sequence of SEQ ID NO: 1.

See D2  
7. (Amended) A method for detecting Alzheimer's disease, comprising examining reactivity of one or more antibodies with a body fluid sample from an individual suspected of Alzheimer's disease, wherein said antibodies are obtained by using, as an immunogen, a partial peptide comprising one or more amino acid residue(s) at the phosphorylation sites of phosphorylated tau protein in a paired helical filament and plural amino acid residues before and/or after the phosphorylation site(s) of amino acid sequence of SEQ ID NO:1, wherein the phosphorylation site(s) are one or more amino acid residue(s) selected from the group consisting of serine at position 198, serine at position 199, threonine at position 231, serine at position 235,

C7  
CONF.  
D2

serine at position 262, serine at position 396, threonine at position 403, serine at position 404, serine at position 409, serine at position 412, serine at position 413, and serine at position 422 of amino acid sequence of SEQ ID NO: 1.

---

Please add the following new claims:

---

18

--8. The reagent kit according to claim 6, wherein the partial peptide is selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15 and SEQ ID NO: 16.

9. The method for detecting Alzheimer's disease according to claim 7, wherein the partial peptide is selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15 and SEQ ID NO: 16.

10. An antibody specifically recognizing a partial peptide of a phosphorylated tau protein in a paired helical filament, said phosphorylated tau protein comprising the amino acid sequence of SEQ ID No: 1, said partial peptide comprising one or more phosphorylated sites of said phosphorylated tau protein, said phosphorylated site(s) being one or more amino acid residues of SEQ ID NO: 1 selected from the group consisting of serine at position 198, threonine

at position 231, serine at position 235, serine at position 262, threonine at position 403, serine at position 404, serine at position 409, serine at position 412, serine at position 413, and serine at position 422.

*Sub D3 cont*  
11. The antibody according to claim 10, wherein the partial peptide comprises (a) said phosphorylated sites of (i) threonine at position 231 and serine at position 235, or (ii) serine at position 412 and serine at position 413, and (b) a plurality of amino acid residues before and/or after said phosphorylation sites of the phosphorylated tau protein of SEQ ID NO:1

12. The antibody according to claim 10, wherein the partial peptide is 1 to 7 amino acid residues in length.

13. The antibody according to claim 12, wherein the partial peptide is 3 to 5 amino acid residues in length.

14. The antibody according to claim 10, which is a monoclonal antibody.

*Sub D4*  
15. The antibody according to claim 10, wherein the partial peptide is selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15 and SEQ ID NO: 16.

16. A reagent kit comprising one or more antibodies specifically recognizing a partial peptide of a phosphorylated tau protein in a paired helical filament, said phosphorylated tau protein comprising the amino acid sequence of SEQ ID No: 1, said partial peptide comprising one or more phosphorylated sites of said phosphorylated tau protein, said phosphorylated site(s) being one or more amino acid residues of SEQ ID NO: 1 selected from the group consisting of serine at position 198, serine at position 199, threonine at position 231, serine at position 235, serine at position 262, serine at position 396, threonine at position 403, serine at position 404, serine at position 409, serine at position 412, serine at position 413, and serine at position 422.

17. A method for detecting Alzheimer's disease comprising reacting one or more antibodies according to claim 10, with a body fluid sample from an individual suspected of having Alzheimer's disease, to determine from the reactivity of said antibodies whether said individual has Alzheimer.--

REMARKS

Favorable reconsideration is respectfully requested in view of the foregoing amendments and the following remarks.

With respect to Applicants' claim for foreign priority, Applicants wish to note that the Examiner's statement that the certified copy of the foreign priority document has not been filed, is incorrect. In the Notification of Acceptance of Application under 35 USC § 371, a copy of which is enclosed herewith, the Patent Office has indicated that the priority document was